High-Dose Versus Low-Dose Systemic Steroids in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Systematic Review

Abstract

Background: Treatment of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with systemic steroids reduces treatment failure, shortens hospital length of stay, improves lung function, and reduces dyspnea. However, it can also cause hyperglycemia, delirium, fluid retention, and other side effects. The balance of these desirable and undesirable effects probably varies according to the steroid dose. Methods: We asked the question, "Should patients having an AECOPD receive low-dose or high-dose systemic steroids?" We searched Medline and the Cochran Central Register of Controlled Trials (CENTRAL) using a sensitive search strategy built around the medical subject heading, "COPD," and variations of the keywords exacerbation, steroids, and randomized trials. Our search yielded 1702 articles in Medline and 885 articles in CENTRAL; we reviewed the full text of 35 articles and selected 11 studies that met the following conditions: randomized trial, enrolled patients having an AECOPD, compared one systemic steroid regimen to another, measured clinical outcomes, and was published in a peer-reviewed journal. Results: None of the selected trials directly compared the effects of different systemic steroid doses on clinical outcomes in patients with AECOPD. Four trials compared durations of steroid treatment, 3 trials compared types of steroids, 1 trial compared routes of steroid delivery, and 3 trials compared multiple variables. Conclusion: There is a paucity of data to support the selection of a systemic steroid dose in patients having an AECOPD. Randomized trials that measure patient-centered outcomes and compare doses of systemic steroids in patients having an AECOPD are needed.